Sign In
|
Register
|
About San Anselmo
|
Contact Us
San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast
|
Traffic
San Anselmo News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
San Anselmo Gas Prices
Ski And Snow Reports
Financial Markets
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Attractions
Antiques
Nightlife
Family Activities
Arts & Culture
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Apartment Finding & Rentals
Apartments
Senior Apartments
Art & Culture
Galleries & Dealers
Museums
Theatres
Associations, Foundations and Organizations
Business & Professional Clubs
Chambers of Commerce
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Sales Organizations
Attractions & Entertainment
Amusement & Water Parks
Galleries
General Attractions
Museums
Parks & Preserves
Theatre
Automotive
Dealers - Antique & Classic
Dealers - New
Dealers - Used
Motorcycles
Parts & Supplies
Repair & Service
Beauty & Fitness
Barbers
Beauty Salons
Dance Clubs & Studios
Fitness Programs
Health Clubs & Gyms
Massage
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business Legal Services
Communications Services
Computer & Audio Visual Services
Consultants
Copier & Fax Services, Equipment
Data Processing Service
Durable Goods
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Management Services
Marketing & Advertising Services
Media Services
Office Furniture, Equipment & Supplies
Photography
Printing & Publishing
Public Relations & Publicity
Research
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Telecommunications
Trucking & Hauling
Video Production
Commercial Contractors
Concierge & Lifestyle Services
Contractors
Architects
Building Contractors & Consultants
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Pet Sitting and Day Care
Education
Art Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Middle Schools
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Appraisers
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Misc. Financial Services
Mortgage Lenders
Personal
Government
Post Offices
Health and Medicine
Alternative Medicine / Acupuncture
Animal Health
Chiropractors
Counseling
Dentistry
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Massage
Medical Doctors
Mental Health
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Accessories
Bed & Bath
Cabinets, Racks & Shelves
Carpets & Rugs
Cleaning Supplies & Services
Contractors
Electric
Floor Coverings
Furniture
Heating, Cooling & AC
Home Improvement Centers
Kitchen
Lamps & Lighting
Lawn & Garden
Masonry & Stone Work
Nurseries & Garden Centers
Painting & Wallcoverings
Plumbing
Tree Services
Insurance
Agents & Brokers
Auto
Health
Home
Life
Pets
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Food & Beverage
Media
Cable & Pay TV Services
Print Publications
Television Stations
Meeting & Event Planning
Audio & Visual
Event Facilities
Exhibit Designers
Lodging
Meeting Planners
Party Rentals & Entertainment
Travel Arrangement & Services
Miscellaneous
Nightlife
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Personal Service
Barbers, Beauty Salons & Spas
Shoe Repair
Pets
Pet Shops
Training
Veterinary Hospitals
Real Estate
Appraisers
Commercial
Condominiums
Developers
Mortgage Lenders
Property Management
Real Estate Agents and Brokers
Residential
Religion
Relocation
Movers
Storage
Restaurants
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Shopping
Accessories
Antiques
Books
Bridal Shops
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Convenience Stores
Department Stores
Discount Stores
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Gourmet & Specialty Foods
Grocery Stores
Health Food Stores
Home Improvement
Indian Arts & Crafts - Retail
Jewelry
Men's Clothing Stores
Notions
Office Supplies & Service
Pharmacies
Repair Shops
Resale Shops
Shoe Stores
Sporting Goods
Thrift Stores
Videos
Women's Clothing Stores
Spas
Beauty Salons
Sports & Recreation
Bicycles
Dance Clubs & Studios, Instruction
Health Clubs
Instruction
Recreation Facilities
Sporting Goods
Technology
Communications
Computer Maintenance and Repair
Computer Services & Consultants
E-commerce
Internet Advertising & Services
Semiconductor
Software
Web Design
Web Development
Travel & Transportation
Hotels & Resorts
Taxi, Limousine & Shuttle
Travel Agencies
Weddings
Bridal Shops
Entertainment
Florists
Health & Beauty
Photographers & Videographers
Apartments
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in San Anselmo
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
29.72
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Genmab A/S ADR
< Previous
1
2
Next >
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Genmab A/S
Via
Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Pfizer Inc.
Via
Business Wire
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
April 03, 2024
From
Genmab A/S
Via
Business Wire
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 27, 2024
From
Genmab A/S
Via
Business Wire
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024
From
Genmab A/S
Via
Business Wire
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Genmab A/S
Via
Business Wire
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Pfizer Inc.
Via
Business Wire
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
December 09, 2023
From
Genmab A/S
Via
Business Wire
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
November 27, 2023
From
Genmab A/S
Via
Business Wire
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
November 02, 2023
From
Genmab A/S
Via
Business Wire
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
October 22, 2023
From
Seagen Inc.
Via
Business Wire
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
September 25, 2023
From
Genmab A/S
Via
Business Wire
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
September 25, 2023
From
Genmab A/S
Via
Business Wire
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
September 04, 2023
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
September 04, 2023
From
Genmab A/S
Via
Business Wire
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
July 21, 2023
From
Genmab A/S
Via
Business Wire
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
June 27, 2023
From
Genmab
Via
Business Wire
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
June 22, 2023
From
Genmab
Via
Business Wire
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
June 09, 2023
From
Genmab
Via
Business Wire
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
May 25, 2023
From
Genmab A/S
Via
Business Wire
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
May 19, 2023
From
Genmab A/S
Via
Business Wire
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From
Genmab
Via
Business Wire
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
December 21, 2022
From
Genmab A/S
Via
Business Wire
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
December 11, 2022
From
Genmab A/S
Via
Business Wire
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
November 21, 2022
From
Genmab
Via
Business Wire
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
November 03, 2022
From
Genmab A/S
Via
Business Wire
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
October 28, 2022
From
Genmab A/S
Via
Business Wire
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
August 05, 2022
From
Genmab A/S
Via
Business Wire
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
July 18, 2022
From
Genmab A/S
Via
Business Wire
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
June 11, 2022
From
Genmab
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
San Anselmo
|
San Anselmo News
|
San Anselmo Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Calendar
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.